Edwards Lifesciences (NYSE:EW) VP Sells $85,626.57 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $84.03, for a total transaction of $85,626.57. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,848,828.06. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Edwards Lifesciences Trading Down 1.4%

EW opened at $83.06 on Monday. The company has a fifty day moving average price of $81.62 and a two-hundred day moving average price of $79.05. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a market cap of $48.20 billion, a P/E ratio of 35.80, a price-to-earnings-growth ratio of 3.73 and a beta of 0.97. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the business posted $0.67 EPS. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on EW. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a research report on Monday, November 3rd. UBS Group set a $92.00 price objective on shares of Edwards Lifesciences in a report on Friday, December 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Canaccord Genuity Group set a $89.00 target price on shares of Edwards Lifesciences in a research report on Friday, December 5th. Finally, Stifel Nicolaus set a $100.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, December 5th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $93.30.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in EW. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at about $25,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $27,000. Rosenberg Matthew Hamilton purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $28,000. Finally, True Wealth Design LLC lifted its holdings in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.